AngioDynamics receives CE Mark approval in Europe for AlphaVac F1885 System [Seeking Alpha]
AngioDynamics, Inc. (ANGO)
Last angiodynamics, inc. earnings: 4/7 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.angiodynamics.com/investor-relations
Company Research
Source: Seeking Alpha
“The CE Mark represents a major step forward in enhancing patient care and safety for endovascular therapies in the EU, a market with a higher prevalence of PE when compared to the United States,” said Laura Piccinini, AngioDynamics Senior Vice President/General Manager, Endovascular Therapies and International. The CE Mark for the AlphaVac F18 System expands treatment options for healthcare professionals in the EU by offering a tool that helps reduce thrombus burden and improve right ventricular function in patients with PE, the company said. Recommended For You More Trending News About ANGO Stock Related Stocks Trending Analysis Trending News
Show less
Read more
Impact Snapshot
Event Time:
ANGO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANGO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANGO alerts
High impacting AngioDynamics, Inc. news events
Weekly update
A roundup of the hottest topics
ANGO
News
- ANGO Initiates RECOVER-AV Trial for AlphaVac F1885 in Europe [Yahoo! Finance]Yahoo! Finance
- AngioDynamics, Inc. (NASDAQ: ANGO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.MarketBeat
- AngioDynamics initiates thrombectomy system trial across Europe [Yahoo! Finance]Yahoo! Finance
- AngioDynamics Initiates RECOVER-AV Clinical Trial Assessing AlphaVac F1885 System in Treatment of Pulmonary Embolism and Long-Term Functional Outcomes [Yahoo! Finance]Yahoo! Finance
- AngioDynamics Initiates RECOVER-AV Clinical Trial Assessing AlphaVac F1885 System in Treatment of Pulmonary Embolism and Long-Term Functional OutcomesBusiness Wire
ANGO
Earnings
- 7/16/24 - Beat
ANGO
Sec Filings
- 9/26/24 - Form DEFA14A
- 9/26/24 - Form DEF
- 8/2/24 - Form 4
- ANGO's page on the SEC website